

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

#9

WOODARD, EMHARDT, NAUGHTON, MORIARTY & MCNETT
PATENT AND TRADEMARK ATTORNEYSBANK ONE CENTER/TOWER
111 MONUMENT CIRCLE, SUITE 3700
INDIANAPOLIS, INDIANA 46204-5137**FAX COVER SHEET**NO. OF PAGES: COVER SHEET PLUS **19** PAGE(S)TO: **Ms. Campbell**FAX NO.: **703-746-6705**SERIAL
NUMBER: **09/719,362**FROM **Gregory B. Coy**DATE: **July 25, 2002**

Confirmation of receipt not requested. Original copy and any enclosures will not be sent. If problems occur during transmission, please contact us at one of the following:

VOICE PHONE number: (317) 634-3456

PRIMARY FAX number: (317) 637-7561 or 7525

Per our discussion of July 24, 2002 regarding the above referenced patent application, attached are copies of the Submission of Sequence Listing in Paper and Computer Readable Form in Response to Second Notice Of Missing Parts which was submitted to the PTO via first class mail on September 12, 2001. Also enclosed is a copy of the returned post card confirming the receipt thereof.

THIS MESSAGE IS INTENDED ONLY FOR THE ADDRESSEE(S) IDENTIFIED ABOVE.

It may contain privileged, confidential, attorney work product, or trade secret information that is exempt from disclosure under applicable laws. If you are not the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this message is strictly prohibited. If you have received this facsimile in error, please notify the sender immediately by telephone and return the facsimile (and all copies) to the sender by mail at the above address. The sender will reimburse you for reasonable expenses incurred. Thank you.


7-31-02
Docket Submitted
was incorrect
BNC

WALLACE, Andrew
Title: METHOD OF GENERATING NUCLEIC
ACID HYBRIDS FOR MUTATION ANALYSIS
Recorded on September 12, 2001
Serial No. 09/230,572
Filed: December 13, 1999
Docket No. 7397-2

GBC:141674

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)
)
Andrew Wallace)
)
Serial No. 09/719,362)
)
Filed December 11, 2000)
)
METHOD OF GENERATING NUCLEIC)
ACID HYBRIDS FOR MUTATION)
ANALYSIS)
)
US National Stage of PCT/GB99/01691)
International Filing Date June 14, 1999)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on	
September 12, 2001	(Date of Deposit)
Gregory B. Coy	
Name of Registered Representative	
	
September 12, 2001	Date of Signature

September 12, 2001

**SUBMISSION OF SEQUENCE LISTING IN PAPER AND
COMPUTER READABLE FORM IN RESPONSE TO SECOND
NOTICE OF MISSING REQUIREMENTS**

Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the notice of missing requirements dated July 11, 2001, Applicant submits herewith a Sequence Listing on paper and the required Sequence Listing in computer readable form. No fees are believed to be due; however, if any fees are deemed necessary, the Commissioner is hereby authorized to charge payment of any additional fees associated with this application or credit any overpayment to Deposit Account No. 23-3030.

IN THE SPECIFICATION

Please enter the attached new Sequence Listing, pages 1-12, into the application.

Submission of Sequence Listing in Paper and Computer Readable Form
in Response to Second Notice of Missing Requirements
Serial No. 09/719,362
Attorney Docket: 7397-2
Page 1 of 4

Please amend the paragraph extending from page 7, line 24, to page 8, line 6, to read as follows:

5'tcatattagccgctgcattgcc-a-specific seq 3' (SEQ ID NO:32)

5'ggcaatgcagcggctaataatga-a-specific seq 3' (SEQ ID NO:33)

5'agccactacccaaactcctgt-a-specific seq 3' (SEQ ID NO:34)

5'acaggagttaggttagtgct-a-specific seq 3' (SEQ ID NO:35)

5'tgtctactgaacctgcctacct-a-specific seq 3' (SEQ ID NO:36)

5'aggtaggcaggttcagttagaca-a-specific seq 3' (SEQ ID NO:37)

5'cctcattaccggctgtcagactg-a-specific seq 3' (SEQ ID NO:38)

5'cagtctgacagccggtaatgagg-a-specific seq 3' (SEQ ID NO:39)


REMARKS

Entry of the above-amendments is respectfully requested. Included in this communication is an ADDENDUM that provides a marked-up version of the amended portion of the specification to delineate the amendments made in accordance with 37 C.F.R. § 1.121 (b)(1).

In accordance with 37 C.F.R. § 1.821 et seq., applicant hereby submits the Sequence Listing, indicated as new pages 1 through 12, along with a computer readable form of the Sequence Listing. The information recorded in computer readable form is identical to the paper copy of the Sequence Listing, except that the paper copy includes page numbers and the computer readable form does not. The above amendments to the specification are also made to insert reference to SEQ ID numbers. The present amendment is supported in the application as filed, and no new matter is introduced by these amendments.

Entry of the above amendments and examination of the application are
respectfully requested.

Respectfully submitted,

By: 

Gregory B. Coy
Reg. No. 40,967
Woodard, Emhardt, Naughton
Moriarty & McNett
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, IN 46204-5137
(317) 634-3456

PBA/NE/D088165PUS:GBC:141674

Submission of Sequence Listing in Paper and Computer Readable Form
in Response to Second Notice of Missing Requirements
Serial No. 09/719,362
Attorney Docket: 7397-2
Page 3 of 4

Received from <3176377561> at 7/25/02 6:35:43 PM [Eastern Daylight Time]

ADDENDUMIN THE SPECIFICATION

5'tcatattagcgcgtgcattgcc-a-specific seq 3' (SEQ ID NO:32)

5'ggcaatgcagcggctaataatga-a-specific seq 3' (SEQ ID NO:33)

5'agccactacccaaactcctgt-a-specific seq 3' (SEQ ID NO:34)

5'acaggagtttgggtagtggct-a-specific seq 3' (SEQ ID NO:35)

5'tgtctcactgaacctgcctacct--a-specific seq 3' (SEQ ID NO:36)

5'aggtaggcaggttcagttagaca-a-specific seq 3' (SEQ ID NO:37)

5'cctcattaccggctgtcagactg-a-specific seq 3' (SEQ ID NO:38)

5'cagtctgacagccggtaatgagg-a-specific seq 3' (SEQ ID NO:39)

SEQUENCE LISTING

<110> WALLACE, ANDREW
CENTRAL MANCHESTER HEALTHCARE NHS TRUST

<120> NUCLEIC ACIDS

<130> 7397-2

<140> 09/719,362

<141> 2000-12-11

<150> PCT/GB99/01691

<151> 1999-06-14

<150> 9812674.1 GB

<151> 1998-06-12

<160> 39

<170> PatentIn Ver. 2.0

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER
SEQUENCE FOR AMPLIFICATION OF NF2

<400> 1

gtggcaaaca ataccaaatt tac

23

<210> 2

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 12

<222> LocationTo : 12

Other Information : Unknown

CDSJoin : No

<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 2

tgtctcactg anacctgcct acctacccat aaaggaatgt aaaccaac

48

<210> 3
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 3
aggtaggcag gttcagttag acaaccgctc tccaccatc tcaac 44

<210> 4
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 4
agccactacc caaactcctg tatggccctc actcagtcctc tg 42

<210> 5
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 5
acaggagttt gggtagtggt tagagcctca gctggcgctt ac 42

<210> 6
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 6
tcattattagc cgctgcattg ccagatctgc tggaccatc tgc 43

<210> 7
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 7
ggcaatgcag cggetaatat gaaaggctgt cggactgaaa ctg 43

<210> 8
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 8
cttcattacc ggctgtcaga ctgattctca gaaaagctac cattatcag 49

<210> 9
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 9
cagtcctgaca gccggtaatg aggaaggcagt gaagtaaatt tgtggat 47

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 10
aggccaggac tgaccacaca 20

<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 11
catgtgtagg ttttttattt tgcct 25

<210> 12
<211> 23
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER
SEQUENCES FOR AMPLIFICATION OF NF2

<400> 12
tgaccacaca gtgacatcat cag

23

<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 13
gatgtttcag bctcagccat g

21

<210> 14
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 14
tcatatttagc cgctgcattg ccaggaatga taaaccaaga taataaatg

49

<210> 15
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 15
ggcaatgcag cggetaatat gaattctttt gtaatgtttg agttttgag

49

<210> 16
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 16
agccactacc caaactcctg tacctgtgag tggatttccc atg

43

<210> 17
<211> 44
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 17

acaggagttt gggtagtggc taccctcaga cagttttgaa ctgg

44

<210> 18

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 18

tctctcactg aatccgccta cctacttggt tgaggagttt ggtgct

46

<210> 19

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 19

aggtaggcgg attcagtgag agaaccctcc cactatctaa ggtaattg

48

<210> 20

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 20

taacattcca ggctgtcgga ctgaagtagc tggatgagaa gcgc

44

<210> 21

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 21

cagtcgcaca gcctggaatg ttaatttaat acagactttg ctaccaggac

50

<210> 22

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 22

taaagagtag ctgtactttt ccca1

25

<210> 23

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 23

taaatecttg tgtctctctgc tg

22

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PRIMER TO
AMPLIFY hMLH1 GENE

<400> 24

aagccatacc tgggggttg

18

<210> 25

<211> 256

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism: +UNKNOWN

<400> 25

tctgtgtgac tactcctggt gtagcttttaa aatagcttta ctgtttgtaa aatgatgcat 60
aattataaaa gtggcaaaaca ataccaaatt tacttcatgt gtaggttttt tattttgctc 120
tatttttttg taggtaataa atctgtatca gatgactccg gaaatgtggg aggagagaat 180
tactgcttgg tacgcagagc accgagggcg agccaggtga ggccattca ttgttggttt 240
acattccttt atgggc 256

<210> 26

<211> 240

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:+UNKNOWN

<400> 26

```
gaatgcttga ttgggtggcc caccgctct ccacccattc cacttagctc caatgacagt 60
gtcttccggt cccccacag ggatgaagct gaaatgggat atctgaagat agtcaggac 120
ctggagatgt acggtgtgaa ctactttgca atccgggtgt gttgaaacct ctctgagctc 180
cttgtgtagt agacagagac tgagt:gaggg ccaggactgc taaaatggtt actttctcat 240
```

<210> 27

<211> 387

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:+UNKNOWN

<400> 27

```
tctgtggacc tgctgaactg cacatgtgac agtgtgtgdc agattctttg gaagggttgaa 60
taaaattttg agcctcagct ggcgtttaca gtatctgttc ttattggatc cacagaataa 120
aaagggcaca gactgctgc ttggagtggg tgccctgggg ctccacattt atgacctga 180
gaacagactg accccaaga tctccttccc gtggaatgaa atccgaaaca tctcgtacag 240
tgacaaggag gtaggacatg tgtgtactgc agatgggtcc agcagatctt tccctgtctg 300
ccccctcacc tggagcctcc ccagccaggg catctccttg ttattcatag agtcctttaa 360
ttcccaggct ttgaggggtg ggttgttt 387
```

<210> 28

<211> 315

<212> DNA

<213> Unknown

<220>

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 54

LocationTo : 54

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 68

LocationTo : 68

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 112

LocationTo : 112

Other Information : Unknown

CDSJoin : No

<223> Description of Unknown Organism:+UNKNOWN

<400> 28

```

gacttgggtgc tcctaattcc ctgaggttta gtgcctggat actgggaagc cagnacaagg 60
gcataacntc atgctgggtct gtggccagtg tggttgcgca tttgtggaat tnccaattgc 120
tggtaacatt ccaggctgtc ggactgaaac tgtgttctgc ttcattcttc cagtttacta 180
ttaaaccact ggataagaaa attgatgtct tcaagtttaa ctctcaaaag cttcgtgtta 240
ataagctggc aagttgagat cctggttaagt tgagatcctg gttttcatta ctgataatgg 300
tagcttttct gagaa                                     315

```

<210> 29

<211> 269

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism:+UNKNOWN

<400> 29

```

tgctacctgc aagagctcaa actgctatgg cactagtggg ccagtaggca gtgaagtaaa 60
tttgtggata ttaacctttt tgtctgcttc tgtggccaca gattctccag ctatgtatcg 120
ggaaccatga tctatttatg aggagaagga aagccgattc tttggaagtt cagcagatga 180
aagcccaggc cagggaggag aaggctagaa agcaggtgag cacaaccttg ttttaactga 240
tgatgtcact gtgtggtcag tcctggcct                                     269

```

<210> 30

<211> 579

<212> DNA

<213> Unknown

<220>

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 6

LocationTo : 6

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 375

LocationTo : 375

Other Information : Unknown

CDSJoin : No

Feature

Sequence:

<221> Unsure

<222> LocationFrom : 537
 LocationTo : 537
 Other Information : Unknown
 CDSJoin : No

<223> Description of Unknown Organism:SEQUENCE OF NF2
 GENE DETERMINED BY USE OF PRIMER 11

<400> 30
 tttccttttg gtaggtaata aatctgtatc agatgactcc ggaaatgtgg gaggagagaa 60
 ttactgcttg gtacgcagag caccgagggc gagccaggtg agggccattc attgttgggt 120
 tacattcctt tatgggtagg taggcagggt cagtggagaca accgctctcc acccatctca 180
 ctttagctcca atgacagtgt ctccggttct cccacacagg atgaagctga aatggaatat 240
 ctgaagatag ctgagacact ggagatgtac ggtgtgaact actttgcaat ccgggtgtgt 300
 tgaaacctct ctgagctcct tgtgtagtag acagagactg agtgagggcc atacaggagt 360
 ttgggtagtg gctanagcct cagctggcgc ttacagtagc tgttcttatt ggatccactg 420
 aataaaaagg gcacagagct gctgttggga gtggatgccc tggggcttca catttatgac 480
 cctgagaaca gactgacccc caagatctcc tccccgtgga atgaaatccg aaacatntcg 540
 tacagtgcac aggaggtagg acatgtgtgt actgcaaat 579

<210> 31
 <211> 586
 <212> DNA
 <213> Unknown

<220>

Feature

Sequence:

<221> Unsure
 <222> LocationFrom : 581
 <222> LocationTo : 581
 Other Information : Unknown
 CDSJoin : No

<223> Description of Unknown Organism:SEQUENCE OF NF2
 GENE DETERMINED USING PRIMER 12

<400> 31
 taaaacaagg ttgtgtcac ctgctttcta gccttctcct ccttggcctg ggctttcact 60
 tgetgaactt ccaaagaatc ggctttcctt ctccctcataa atagatcatg gtccccgata 120
 catagctgga gaatctgtgg ccacagaagc agacaaaaag gttaatatcc acaaatttac 180
 ttcactgctt cctcattacc ggctgtcaga ctgatttcta gaaaagctac cattatcagt 240
 aatgaaaacc aggatctcaa cttaccagct tattaacacg aagctttgag gagttaaaact 300
 tgaagacatc aattttctta tccagtgggt taatagtata ctggaagaat gaagcagaac 360
 acagtttcag tccgacagcc tttcatatta gccgtgcac tgccagatct gctggacca 420
 tctgcagtac acacatgtcc tacctccttg tcaactgtac agatgtttcg gatttcattc 480
 caggggaagg agatcttggg ggtcagtcct gttctcagg cataaatgtg aagccccagg 540
 gcattccact caagcagcag ctctggccct ttttatccag nggac 586

<210> 32
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>

<221> misc_feature

<222> (23)

<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 32

tcattattagc cgctgcattg cca

23

<210> 33

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>

<221> misc_feature

<222> (23)

<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 33

ggcaatgcag cggctaatat gaa

23

<210> 34

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>

<221> misc_feature

<222> (22)

<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 34

agccactacc caaactcctg ta

22

<210> 35

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>

<221> misc_feature
<222> (22)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 35
acaggagttt gggtagtgga ta

22

<210> 36
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 36
tgtctcactg aacctgccta ccta

24

<210> 37
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 37
aggtaggcag gttcagtga acaa

24

<210> 38
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 38
cctcattacc ggctgtcaga ctga

24

<210> 39
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER PRIMER
SEQUENCE

<220>
<221> misc_feature
<222> (24)
<223> LINKED TO PRIMING PORTION OF LINKER PRIMER

<400> 39
cagtctgaca gccggtaatg agga

24

Matter No. 7397-2Initials: TQH/GBC/pab 9/12/2001

PLEASE RETURN THIS CARD

☒ Patent ☐ Trademark
☐ Copyright

Serial No. 09/719,362
Applicant: WALLACE, Andrew
METHOD OF GENERATING NUCLEIC
ACID HYBRIDS FOR MUTATION
ANALYSIS

Receipt of the attached is
acknowledged.

☐ Application
☐ Check for \$ _____
☐ _____ sheets of drawing(s)
☐ Small Entity Declaration
☐ Declaration & Power of Atty.
☐ Assignment
☐ Amendment
☐ Req. for Extension of Time
☐ Specimens
☐ Information Disclosure Statement
☒ Subm. of Seq. Listing/
☐ Response to 2nd Not. of
☐ Missing Parts

Matter No. 7397-2Initials: TQH/GBC/pab 9/12/2001**PLEASE RETURN THIS CARD**

(XX) Patent () Trademark
() Copyright

Serial No. 09/719,362
Applicant: WALLACE, Andrew
METHOD OF GENERATING NUCLEIC
ACID HYBRIDS FOR MUTATION
ANALYSIS

533 Rec'd PCT/PTO 15 SEP 2001
Receipt of the attached is
acknowledged.

- () Application
() Check for \$ _____
() _____ sheets of drawing(s)
() Small Entity Declaration
() Declaration & Power of Atty.
() Assignment
() Amendment
() Req. for Extension of Time
() Specimens
() Information Disclosure Statement
(X) Subm. of Seq. Listing/
() Response to 2nd Not. of
() Missing Parts